Status:
COMPLETED
A Study of ABT-751 in Patients With Renal Cell Cancer
Lead Sponsor:
Abbott
Conditions:
Renal Cell Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Renal Cell Carcinoma.
- Recurrent tumor.
- At least 6 weeks post-nephrectomy.
- Able to tolerate normal activities of daily living.
- Adequate bone marrow, kidney, and liver function.
- Exclusion Criteria
- Pregnant or breast feeding.
- Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
- CNS metastasis.
Exclusion
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00073112
Start Date
August 1 2003
End Date
September 1 2006
Last Update
November 29 2007
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Cancer Research Center
Tucson, Arizona, United States, 85712
2
UCLA School of Medicine
Los Angeles, California, United States, 90024
3
Clinical Trials + Research Associates
Montebello, California, United States, 90640
4
US Oncology Inc Rocky Mountain Cancer Centers
Denver, Colorado, United States, 80218